Volume 4.49 | Dec 13

Cord Blood News 4.49 December 13, 2012
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
TOP STORY
Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture
Poor engraftment due to low cell doses restricts the usefulness of umbilical-cord-blood transplantation. Researchers hypothesized that engraftment would be improved by transplanting cord blood that was expanded ex vivo with mesenchymal stromal cells. [N Engl J Med] Abstract | Press Release

New StemSpan(TM) SFEM II - for optimal CD34+ cell expansion of bone marrow and cord blood cells
PUBLICATIONS (Ranked by impact factor of the journal)

Double Unit Grafts Successfully Extend the Application of Umbilical Cord Blood Transplantation in Adults with Acute Leukemia
The transplantation of two partially HLA-matched umbilical cord blood (UCB) units has been adopted as a simple approach for increasing the total nucleated cells. The authors sought to determine whether the relative safety and efficacy of this approach was comparable to a single UCB transplant. [Blood] Abstract

Enhanced Normal Short Term Human Myelopoiesis in Mice Engineered to Express Human-Specific Myeloid Growth Factors
Investigators showed that five-fold more human myeloid cells are produced in sublethally irradiated NOD/SCID-IL-2Receptor-γchain-null (NSG) mice engineered to constitutively produce human interleukin-3, granulocyte-macrophage colony-stimulating factor and Steel Factor than in regular NSG mice three weeks after an intravenous injection of CD34+ human cord blood cells. [Blood] Abstract

Comparative Proteomic Analysis of Endothelial Cells Progenitor Cells Derived from Cord Blood- and Peripheral Blood for Cell Therapy
The authors established endothelial progenitor cells derived from cord blood- and peripheral blood and investigated their fundamental differences at the cellular and molecular levels through a combination of stem cell biology techniques and proteomic analysis. [Biomaterials] Abstract

Umbilical Cord Blood-Derived Mesenchymal Stem Cells Inhibit, but Adipose Tissue-Derived Mesenchymal Stem Cells Promote Glioblastoma Multiforme Proliferation
To examine the anticancer therapeutic application of mesenchymal stem cells (MSC) from different sources, researchers established two different kinds of human MSC: umbilical cord blood-derived MSC and adipose tissue-derived MSC. They used these MSC in a co-culture assay with primary glioblastoma multiforme (GBM) cells to analyze how MSC from different sources can inhibit GBM growth. [Stem Cells Dev] Abstract

The Metabolomic Profile of Umbilical Cord Blood in Neonatal Hypoxic Ischemic Encephalopathy
Researchers aimed to describe and quantify the metabolomic profile of umbilical cord blood samples in a carefully defined population of full-term infants with hypoxic ischemic encephalopathy. [PLoS One]
Full Article

Transplantation of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells or Their Conditioned Medium Prevents Bone Loss in Ovariectomized Nude Mice
Researchers studied the effects of systemic injection of human umbilical cord blood-mesenchymal stem cells and their conditioned medium on ovariectomy-induced bone loss in nude mice. [Tissue Eng Part A] Abstract

Cryopreservation of Hematopoietic Stem and Progenitor Cells Amplified Ex Vivo from Cord Blood CD34+ Cells
Transplantation of ex vivo expanded cord blood cells is becoming a reality, while the issue of expanded cells’ cryopreservation emerges as an option that allows the conservation of the product for transportation and future use. Here, researchers investigated whether it is possible to maintain the functional hematopoietic stem cell and committed progenitor properties after freezing and thawing of expanded cells. [Transfusion] Abstract

Avoiding Room Temperature Storage and Delayed Cryopreservation Provide Better Postthaw Potency in Hematopoietic Progenitor Cell Grafts
Viable cell counts by flow cytometry and colony-forming unit recoveries were assessed on cord blood, mobilized peripheral blood stem cell, and bone marrow samples over 72 hours using two different storage conditions, refrigerated (4-8°C) or room temperature (19-22°C). To determine the effects of delayed freezing on progenitor recoveries, paired samples were evaluated before and after cryopreservation. [Transfusion] Abstract

Influence of the AT2 Receptor on the L-Arginine-Nitric Oxide Pathway and Effects of (-)-Epicatechin on HUVECs from Women with Preeclampsia
The production of nitric oxide and arginase activity were investigated in plasma and human umbilical vein endothelial cells (HUVECs) from women with preeclampsia, which were associated with arginase II, eNOS, caveolin, angiotensin 1 and 2 receptor expression (AT1R and AT2R, respectively). [J Hum Hypertens] Abstract

Enhanced Survival and Neurite Network Formation of Human Umbilical Cord Blood Neuronal Progenitors in Three-Dimensional Collagen Constructs
Researchers explored the survival and differentiation of human cord blood-derived neuronal progenitors in a three-dimensional (3D) collagen construct. In contrast to two-dimensional culture conditions, the cells survived in 3D for an extended period of time of more than two months. [J Mol Neurosci]
Abstract | Full Article

StemSpan ACF: The WORLD'S FIRST Plasma Component-Free Hematopoietic Expansion Medium. Come learn more.

REVIEWS
The Therapeutic Potential, Challenges and Future Clinical Directions of Stem Cells from the Wharton’s Jelly of the Human Umbilical Cord
Stem cells derived directly from the uncontaminated Wharton’s jelly appear to offer the best clinical utility because of their unique beneficial properties. This review critically evaluates their therapeutic value, the challenges and future directions for their clinical application. [Stem Cell Rev] Abstract
INDUSTRY NEWS

GE Healthcare Life Sciences Opens New £3 Million Laboratories for Cell Science in Cardiff, Wales
GE Healthcare Life Sciences announced the opening of its new £3 million cell science laboratories in Cardiff, Wales. The state-of-the-art investment at the company’s Maynard Centre creates a world-class facility for research and technology innovation in cell science, to help advance the rapidly emerging fields of cell therapy and cell bioprocessing, and to support the development of new, more effective and safer medicines. [GE Healthcare Life Sciences] Press Release

Alliance for Regenerative Medicine Forms Tissue Engineering and Biomaterials Committee
The Alliance for Regenerative Medicine announced the formation of a Tissue Engineering and Biomaterials Committee (TEBC). The TEBC has been established to assemble the companies, academic institutions, and organizations within the Alliance for Regenerative Medicine that develop and commercialize tissue engineered and biomaterial based technologies. [Alliance for Regenerative Medicine] Press Release

BloodCenter of Wisconsin and Heartland Blood Centers to Form Strategic Alliance
BloodCenter of Wisconsin and Heartland Blood Centers, Aurora, Ill., announced they will form a strategic alliance that will offer a more comprehensive range of transfusion medicine services to hospitals. This alliance will help improve patient outcomes and create operational efficiencies. [BloodCenter of Wisconsin] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS
NEW 2013 Gordon Conference on Stem Cells and Cancer
April 21-26, 2013
Les Diablerets, Switzerland

View our events page to see a complete list of events in the cord blood community.
JOB OPPORTUNITIES

Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

Quality Control Analyst (STEMCELL Technologies, Inc.)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Postdoctoral Research Scientist – Regenerative Stem Cell Research (Oxford NHS Blood and Transplant)

Part-Time Postdoctoral Research Scientist – Regenerative Stem Cell Research (Oxford NHS Blood and Transplant)

Research Technologist – Stem Cells and Cancer (Massachusetts General Hospital & Harvard Medical School)


Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Cord Blood News: Archives | Events | Contact Us